Clinical Trials Browser

Withdrawn × Breast × 1 year × Clear all

NCT06229392 2026-03-11

A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer

Phase 1 Withdrawn

Breast Neoplasms, Influenza, Human, Triple Negative Breast Neoplasms

NCT03804255 2026-03-02

Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting

BreastDermatologicGastrointestinalThoracic

Breast Neoplasms, Lung Neoplasms, Melanoma, Colorectal Neoplasms

NCT07439432 2026-02-27

Stereotactic Guided Biopsy and Cryoablation

Phase NA Withdrawn

Breast Neoplasms

NCT05014295 2026-02-24

Patient Recall of Cancer Screening and Diagnosis

Phase NA Withdrawn

BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT06829199 2026-02-19

MK-5890-003

Phase 2 Withdrawn

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06868238 2026-02-18

Evaluation of Novel Iron-based Lymphatic Mapping Agent, Magtrace, for Delayed Sentinel Lymph Node Biopsy (SLNB) in Ductal Carcinoma In-Situ (DCIS)

Phase 2 Withdrawn

Carcinoma, Intraductal, Noninfiltrating, Lymphedema

NCT06585969 2026-02-12

DISCORDANT

Phase 3 Withdrawn

Breast Neoplasms

NCT05512260 2026-02-11

BESTa

Phase NA Withdrawn

BreastGastrointestinalGynecologic

Breast Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT04273555 2026-02-06

Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging

Phase 1/2 Withdrawn

HER2-positive Breast Cancer

NCT07226102 2026-02-04

Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic or Breast Cancer

Phase NA Withdrawn

BreastGynecologic

Genital Neoplasms, Female, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06613516 2025-12-24

CaptAin

Phase 2 Withdrawn

Breast Neoplasms

NCT05957042 2025-12-10

Pilot Study to Evaluate if Contrast Enhanced Ultrasound (CEUS) Can Predict Treatment Response in Triple Negative Breast Cancer (TNBC) Patients Receiving Combined Chemotherapy and Immune Checkpoint Inhibitors (ICI).

Phase EARLY_PHASE1 Withdrawn

Breast Neoplasms

NCT07150767 2025-12-02

A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast Cancer

Phase 1 Withdrawn

Locally Advanced Breast Cancer (LABC)

NCT07076680 2025-11-28

A Real-World Study in Patients With HR+/HER2- Advanced Breast Cancer

Breast Cancer Metastatic

NCT07092475 2025-11-26

The Impact of Intraoperative Methadone on Postoperative Opioid Use

Phase 3 Withdrawn

Breast Neoplasms

NCT02825810 2025-11-18

Cervical Motor Control in Long-term Breast Cancer Survivors

Phase NA Withdrawn

Breast Neoplasms, Neck Pain

NCT05634954 2025-10-23

Study to Evaluate Safety and Dosimetry of [18F]GEH121224 in Patients With Locally Advanced or Metastatic Breast Cancer

Phase 1 Withdrawn

Breast Neoplasms

NCT04419181 2025-10-14

Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer

Phase 2 Withdrawn

HER2-positive Breast Cancer

NCT04794816 2025-10-14

What Women Want: Real Time Results During Screening Mammography in the Era of Patient-Experience Driven Care

Breast Neoplasms

NCT06884254 2025-10-14

EGC102

Phase 3 Withdrawn

Breast Neoplasms

NCT03974204 2025-09-26

Analyses of Exosomes in the Cerebrospinal Fluid for Breast Cancer Patients With Suspicion of Leptomeningeal Metastasis.

Phase NA Withdrawn

Breast Neoplasms, Meningeal Carcinomatosis

NCT06672224 2025-09-17

Indocyanine Green Fluoroscopy and SPY Angiography for the Assessment of Lymphatic Structure in Breast Cancer Patients at Risk for Breast Cancer-Related Lymphedema

Phase NA Withdrawn

Breast Cancer Lymphedema, Breast Neoplasms

NCT01827969 2025-09-16

USF

Phase NA Withdrawn

Breast Neoplasms

NCT00466830 2025-09-11

SDPM

Breast Neoplasms, Pain

NCT00210145 2025-09-04

ASE K SEIN

Breast Neoplasms

NCT06084689 2025-09-02

EMPIRE

Phase 2 Withdrawn

BreastGastrointestinalSarcomaThoracic

Tertiary Lymphoid Structures, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Sarcoma, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT04756765 2025-08-17

Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms

NCT05678205 2025-07-30

A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors

Phase 1/2 Withdrawn

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT06246786 2025-07-16

Breast/Cyclosporin A/TNBC (Triple Negative Breast Cancer)

Phase EARLY_PHASE1 Withdrawn

Triple Negative Breast Neoplasms

NCT06590558 2025-07-03

Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer

Phase 1 Withdrawn

Triple Negative Breast Neoplasms

NCT06852560 2025-06-26

GEM

Phase NA Withdrawn

Breast Neoplasms, Atherosclerosis

NCT03941223 2025-06-25

Regional Anesthesia for Breast Surgery

Phase NA Withdrawn

Breast Neoplasms

NCT06494046 2025-06-04

Defining Musical Toxicity and Its Effect on Patient Well-being

BreastCNSGastrointestinalThoracic

Brain Neoplasms, Breast Neoplasms, Esophageal Neoplasms, Lung Neoplasms

NCT01349088 2025-05-02

Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer

Phase 1/2 Withdrawn

Breast Neoplasms

NCT06008301 2025-04-30

Comparing Breast Magnetic Resonance Imaging (MRI) and Contrast-enhanced Mammography (CEM)

Phase NA Withdrawn

Breast Cancer Female

NCT05940844 2025-04-09

Study of OB-002 in Patients With Refractory Metastatic Cancer

Phase 1 Withdrawn

BreastGastrointestinalGenitourinary

Breast Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT04889495 2025-03-19

A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer

BreastGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Kidney Neoplasms, Colorectal Neoplasms